GlassScriptPhysician profile
Tara Mollus
NPI 1437613049
$7,016.47
in general payments reported to CMS, 2019-2025
54 companies · $2,021 in 2025
The $2,021 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $162 · 2023: $1,977 · 2024: $2,857 · 2025: $2,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,366 · Education: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,366.40 |
| Education | $487.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $570.43 | 2023-2025 | |
| Janssen Biotech, INC. | $381.36 | 2023-2025 | Erleada, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $347.41 | 2023-2025 | Lynparza, Calquence, Imfinzi |
| Incyte Corporation | $346.78 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Pfizer INC. | $333.14 | 2021-2025 | |
| Genentech USA, INC. | $322.30 | 2023-2025 | Tecentriq, Polivy, Columvi |
| Celgene Corporation | $273.18 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Merck Sharp & Dohme LLC | $257.45 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $249.12 | 2023-2025 | |
| Glaxosmithkline, LLC. | $237.54 | 2021-2025 | Jemperli, Ojjaara, Blenrep |
| Takeda Pharmaceuticals U.S.A., INC. | $216.39 | 2023-2025 | Ninlaro, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $209.73 | 2023-2025 | Libtayo |
| Astellas Pharma US INC | $207.67 | 2023-2025 | Xtandi, Padcev |
| Daiichi Sankyo INC. | $201.84 | 2023-2025 | Enhertu |
| Array Biopharma INC | $199.36 | 2024-2025 | Mektovi, Braftovi, Tukysa |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $193.17 | 2023-2025 | Tukysa, Padcev, Adcetris |
| E.R. Squibb & Sons, L.L.C. | $163.02 | 2023-2025 | Opdivo, Opdualag, Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $157.92 | 2023-2025 | |
| Lilly USA, LLC | $138.41 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Aveo Pharmaceuticals, INC. | $137.34 | 2024-2025 | |
| Kite Pharma, INC. | $126.36 | 2023-2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $118.91 | 2023-2025 | Qinlock, Romvimza, Tgct |
| Sobi, INC | $103.36 | 2021-2025 | |
| Genzyme Corporation | $99.30 | 2023-2025 | |
| Eisai INC. | $98.95 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $94.76 | 2023-2024 | Ultomiris |
| Sumitomo Pharma America, INC. | $88.59 | 2023-2025 | Orgovyx |
| Beone Medicines USA, INC. | $76.97 | 2025 | Brukinsa, Tevimbra |
| Genmab U.S., INC. | $73.79 | 2023-2025 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $73.72 | 2023 | Imbruvica, Epkinly |
| Pharmaessentia USA Corporation | $73.11 | 2023-2024 | Besremi |
| Coherus Oncology, INC. | $72.72 | 2024-2025 | Loqtorzi |
| Puma Biotechnology, INC. | $71.48 | 2023-2025 | |
| Stemline Therapeutics INC. | $67.10 | 2023-2024 | Orserdu |
| Beigene USA, INC. | $62.96 | 2023-2025 | Brukinsa |
| Exelixis INC. | $62.25 | 2023-2024 | Cabometyx |
| Karyopharm Therapeutics INC. | $53.59 | 2023-2024 | Xpovio |
| Servier Pharmaceuticals LLC | $50.91 | 2024 | |
| Progenics Pharmaceuticals, INC. | $46.99 | 2023-2024 | Pylarify |
| Taiho Oncology, INC. | $45.83 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $41.99 | 2024 | |
| Blue Earth Diagnostics | $38.31 | 2023-2024 | |
| Emd Serono, INC. | $35.43 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $24.00 | 2023 | Rezlidhia, Tavalisse |
| Blueprint Medicines Corporation | $21.96 | 2023 | Ayvakit |
| Immunogen, INC. | $18.87 | 2023 | Elahere |
| Morphosys, US INC. | $18.32 | 2023 | Monjuvi |
| Apellis Pharmaceuticals, INC. | $18.07 | 2024 | Empaveli |
| Adaptive Biotechnologies Corporation | $17.74 | 2024 | Clonoseq |
| Myriad Genetic Laboratories, INC. | $16.13 | 2023 | Bracanalysis Cdx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.93 | 2025 | |
| Agios Pharmaceuticals, INC. | $15.60 | 2025 | Pyrukynd |
| Pharmacosmos Therapeutics INC. | $14.61 | 2023 | Monoferric |
| Mirati Therapeutics, INC. | $14.30 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Mollus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.